Live Market Updates
Market headlines from global newswires, updated twice daily at 8:00 AM and 1:00 PM New York time.
45 articles
Live UpdateHistory Says This Is What Happens to Mega-IPO Stocks in Their First 12 Months
Warren Buffett's cautionary stance on IPOs is examined through historical performance data. The article argues that mega-IPO stocks typically underperform in their first 12 months because companies go public during bull markets when valuations are inflated. Additional headwinds include the shift from hype to fundamentals, high initial valuations based on rapid growth expectations, and selling pressure from insider lockup period expirations.
Live UpdateInvestors Just Got Bad News From the Federal Reserve. Here's What History Says Comes Next.
The Federal Reserve plans to maintain higher interest rates for longer, with three more quarter-point increases expected by mid-2027. While higher rates typically pressure stock prices, historical precedent shows market outcomes depend on corporate earnings growth and economic conditions. The S&P 500 remains near all-time highs due to AI-driven earnings, but uncertainty about AI spending cycles and inflation trending toward 4% create risk. Investors are advised to maintain a buy-and-hold strategy and review portfolio concentration in tech and growth stocks.
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
Zymeworks announced a global license and collaboration agreement with Roche for ZW209, a trispecific T cell engager targeting DLL3. Zymeworks will receive $55 million upfront and $40 million upon Phase 1b initiation, with potential for up to $718 million in additional milestone payments and tiered royalties on future net sales. Zymeworks will conduct the Phase 1a trial while Roche funds it and handles subsequent development and commercialization.
EssilorLuxottica announces S&P Global’s rating upgrade to A+
EssilorLuxottica announced that S&P Global Ratings upgraded its long-term credit rating to A+ with a stable outlook. The upgrade reflects the company's strong organic growth, solid cash flow, and robust balance sheet. S&P highlighted the company's strategic evolution into eyecare and medtech as a key growth driver. In Q3 2026, the group reported revenue growth of 9.0% (7.2% at constant currency) to €7,486 million.
EssilorLuxottica annonce le relèvement à A+ de sa note S&P Global Ratings
EssilorLuxottica announced that S&P Global Ratings upgraded its long-term credit rating to A+ with a stable outlook. The upgrade reflects recognition of the company's organic growth trajectory, strong cash flow, robust balance sheet, and strategic shift toward consumer-focused visual health and med-tech leadership. Q3 2026 revenue grew 9.0% to €7,486 million (7.2% at constant currency).
EssilorLuxottica annuncia l’upgrade del rating ad A+ da parte di S&P Global
EssilorLuxottica announced that S&P Global Ratings upgraded its long-term credit rating to A+ with stable outlook. The upgrade recognizes the company's strong organic growth, consistent cash generation, and solid financial position. S&P highlighted the group's strategic evolution toward eyecare and med-tech leadership as a key driver of long-term growth and financial resilience. Q3 2026 revenue grew 9.0% to €7,486 million (7.2% at constant currency).
Questrade Brings Extended-Hours Trading for Pre-Market Equity Options
Questrade announced the launch of pre-market and post-market trading for equity options and index options, becoming one of the first Canadian brokerages to offer extended trading hours powered by Cboe. The service allows traders to respond to earnings reports and economic data outside regular market hours (9:30 am - 4:00 pm ET) with pre-market sessions starting at 7:30 am and post-market sessions extending to 4:15 pm or 5:00 pm depending on the product.
Live UpdateThis All-Star Stock Just Plunged. It Could Be a Massive Buying Opportunity
Sea Limited's stock plunged 20% in two weeks after CEO Forrest Li announced plans to spin off its fintech arm Monee and enter the AI cloud computing business. While investors reacted negatively due to concerns about losing a high-growth business and entering a competitive, capital-intensive field, the author argues these moves could unlock significant value through a conglomerate discount resolution and capitalize on high-demand AI computing capacity.
Live UpdateBetter Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb?
Pfizer offers a higher dividend yield of 5.8% compared to Bristol Myers Squibb's 4.3%, making it more attractive for income investors. However, Bristol Myers Squibb maintains a safer dividend with a 55% payout ratio versus Pfizer's over 100% payout ratio. Both pharma companies face patent cliffs but have growth prospects. The article suggests Pfizer is better for maximizing income, while Bristol Myers Squibb may deliver higher total returns due to lower execution risk.
Start Your Trading Journey
Register, fund, and start trading today, your path to smarter investing begins here.
